Skip to main content

Table 6 Coexisting BRAF and activating RAS or PIK3CA mutations

From: Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

BRAF kinase activity

BRAF a

RAS or PIK3CAa

Coexisting BRAF and RASb

 Class-2 BRAF mutation

p.K601E (35%)

NRAS p.G13 N (34%)

p.G464R (5.5%)

NRAS p.Q61R (55%)

 Class-3 BRAF mutation

p.G466A (30%)

KRAS p.G12D (49%)

p.G466 V (19%)

HRAS p.G13 N (26%)

p.S467 L (26%)

NRAS p.Q61K (24%)

p.D594N (47%)

NRAS p.G12S (42%)

p.D594N (59%)

HRAS p.Q61K (46%)

Coexisting BRAF and PIK3CAc

 Class-1 BRAF mutation

p.V600E (11%)

PIK3CA p.545 K (7.5%)

p.V600K (56%)

PIK3CA p.545 K (24%)

 Class-3 BRAF mutation

p.G466E (17%)

PIK3CA p.545 K (3.1%)

  1. aPercentage in the parenthesis indicates mutant allele frequency
  2. bA case with BRAF p.V600E and HRAS p.Q25* was not included
  3. cIncluding only PIK3CA mutations affecting codons 542, 545 or 1047